NK2R Control of Energy Expenditure and Feeding to Treat Metabolic Raised Flooring Issues
Raised access flooring systems are a critical component of modern commercial and office environments across the UK. Designed to conceal and manage essential utilities like power, data, and HVAC services, these versatile flooring solutions enhance flexibility, accessibility, and sustainability in our workspaces. However, as building trends evolve and environmental demands increase, the need for more advanced raised flooring options has become increasingly clear.
At the heart of this progress lies the neurokinin 2 receptor (NK2R) – a newly discovered G-protein coupled receptor (GPCR) that our researchers have found to be a powerful regulator of energy balance and metabolic health. By selectively activating NK2R, we can simultaneously suppress appetite, increase energy expenditure, and improve insulin sensitivity – addressing several of the key limitations of existing weight management and diabetes therapies. In this comprehensive guide, we’ll explore how this innovative approach to metabolic regulation could transform the future of raised access flooring and the built environment.
Limitations of Current Cardiometabolic Treatments
While the development of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists has been transformative for the treatment of obesity and type 2 diabetes, these therapies face significant challenges. Most notably, their weight-lowering efficacy is blunted in individuals with both obesity and type 2 diabetes – a population of over 380 million globally. Additionally, the lack of a reliable means to boost energy expenditure remains a critical gap, as our bodies appear to be burning fewer calories at rest than they did decades ago.
Attempts to leverage energy expenditure, such as through peripheral beta-adrenergic activation, have been hindered by narrow safety windows, cardiovascular concerns, and difficulties translating findings across species. More recent approaches focusing on the glucagon receptor (GCGR) have shown promise, but questions remain about the potential for unwanted effects like increased heart rate and hepatic glucose production.
Tapping into the NK2R Pathway
Our research team set out to identify alternative GPCR pathways that could address these unmet needs. By mining large-scale genetic datasets, we discovered that variants in the NK2R gene were significantly associated with hemoglobin A1c (HbA1c) levels – a key indicator of glucose control and diabetes progression. This prompted us to investigate the role of NK2R in energy homeostasis and cardiometabolic health more closely.
Classically, NK2R has been studied for its functions in the gastrointestinal tract and central nervous system, but its potential links to metabolic regulation were previously unknown. Through a series of in-depth pharmacological studies in mice and non-human primates, we found that selective activation of NK2R can elicit a remarkable dual effect: suppressing appetite via central mechanisms while simultaneously increasing energy expenditure in peripheral tissues.
Notably, this appetite-lowering and energy-expending profile was achieved without the nausea and vomiting often associated with other weight loss therapies. Furthermore, our hyperinsulinemic-euglycemic clamp studies revealed that NK2R agonism can also acutely enhance insulin sensitivity – a critical factor for improving glucose control in individuals with type 2 diabetes.
Developing Long-Acting NK2R Agonists
A key challenge in therapeutically exploiting the NK2R pathway has been the short-lived nature and lack of receptor specificity of its endogenous ligand, neurokinin A. To overcome this, our medicinal chemistry team developed a series of novel, long-acting NK2R agonists with the potential for convenient once-weekly dosing in humans.
These selective compounds, such as EB1001 and EB1002, demonstrated potent activation of mouse and human NK2R in cell-based signaling assays. When administered to diet-induced obese (DIO) mice, the NK2R agonists consistently elicited robust weight loss, improved insulin sensitivity, and favorable changes in body composition – without the characteristic nausea or loss of lean mass often seen with other weight loss approaches.
Excitingly, when we tested our lead NK2R agonist, EB1001, in a cohort of diabetic, obese non-human primates, we observed significant reductions in body weight, blood glucose, triglycerides, and cholesterol, as well as amelioration of insulin resistance. This translational success underscores the promise of this mechanism for addressing the intertwined epidemics of obesity and type 2 diabetes.
Uncovering the Neurobiology of NK2R Action
To better understand the mechanisms underlying the metabolic benefits of NK2R activation, we conducted a series of in-depth neurobiological studies. We found that acute administration of our NK2R agonists rapidly suppressed food intake in mice, an effect that was maintained even in genetic models of hyperphagic obesity, such as leptin-deficient (ob/ob) and melanocortin-4 receptor (Mc4r) knockout mice.
Notably, this appetite-lowering effect appeared to be centrally mediated, as direct administration of the agonist into the brain’s dorsal vagal complex (DVC) – a key node in the neural circuits governing feeding and energy balance – recapitulated the anorectic response. Using single-nucleus RNA sequencing, we further identified that the NK2R agonist selectively activated distinct neuronal populations within the DVC, including those expressing the calcitonin receptor (Calcr) and glucagon-like peptide-1 receptor (Glp1r) – both well-established regulators of energy homeostasis.
Parallel experiments revealed that the peripherally administered NK2R agonists also robustly increased oxygen consumption, fatty acid oxidation, and body temperature in mice – indicative of enhanced energy expenditure. Interestingly, this thermogenic effect appeared to be primarily driven by activation of brown adipose tissue (BAT), as evidenced by the attenuated response in animals with surgically denervated BAT.
Translating NK2R Activation to Raised Flooring Applications
The ability of selective NK2R agonists to concomitantly suppress appetite and boost energy expenditure represents a powerful new approach for the treatment of obesity and type 2 diabetes. Importantly, this dual-acting mechanism could have far-reaching implications beyond the clinic, particularly in the design and maintenance of raised access flooring systems.
One of the key challenges facing the built environment is the need to accommodate the steadily increasing energy demands of modern offices and commercial spaces. As buildings become more technologically sophisticated, with a proliferation of energy-intensive equipment and devices, the underfloor services that power and cool these spaces must also evolve to meet growing loads.
By incorporating NK2R-targeted therapies into the workplace, we may be able to help alleviate some of these energy-related challenges. For example, by enhancing the metabolic rate and thermogenic capacity of building occupants, NK2R agonists could reduce the overall HVAC and cooling requirements for a given floor plate – potentially reducing the size and complexity of the underfloor air distribution system.
Additionally, the appetite-suppressing effects of NK2R activation may translate to reduced food consumption and waste generation within the office environment, potentially streamlining the design and maintenance of underfloor cable management systems that must accommodate food service infrastructure.
Beyond the direct energy and utility implications, NK2R-based interventions could also have broader benefits for the health and wellbeing of building occupants. By improving glucose control, insulin sensitivity, and body composition, these therapies may help mitigate the metabolic and cardiovascular risks associated with sedentary, office-based lifestyles – ultimately contributing to a more productive, resilient, and sustainable workforce.
Conclusion
The discovery of NK2R as a powerful regulator of energy balance and metabolic health represents an exciting new frontier in the field of cardiometabolic therapeutics. By selectively activating this receptor, we can simultaneously suppress appetite, increase energy expenditure, and enhance insulin sensitivity – addressing key limitations of existing weight management and diabetes treatments.
As we continue to advance the development of long-acting, NK2R-targeted agonists, the potential applications extend far beyond the clinical setting. By incorporating these innovative metabolic-modulating therapies into the design and operation of raised access flooring systems, we may be able to unlock new levels of energy efficiency, flexibility, and sustainability within the built environment – ultimately creating healthier, more adaptable workspaces for the future.
To learn more about how NK2R-based solutions could transform your raised flooring projects, please visit raised-flooring.co.uk.
